

Financial Results for the Fiscal Year Ended March 31, 2014



August 1, 2013
Exchange where listed: TSE

Name of listed company : TERUMO CORPORATION
(URL <http://www.terumo.com/>)
Company code number : 4543
Representative: : Yutaro Shintaku, President and Representative Director
Please address all communications to : Masayuki Maruta, General Manager, Corporate Communication Dept.
Phone : +81 / 3 -6742 -8550
Adoption of U.S. accounting standards [Yes/No]: No

1. Consolidated financial highlights for the interim period ended June 2013 (From April 1, 2013 to June 30, 2013)

(Notes: The amounts shown below ignore values of less than a million yen)

	Net sales		Operating income		Ordinary income		Net income	
	(Millions of yen)	%	(Millions of yen)	%	(Millions of yen)	%	(Millions of yen)	%
Three months ended June, 2013	111,090	15.9	13,329	(13.9)	12,940	(0.3)	8,956	9.8
Three months ended June, 2012	95,867	0.2	15,481	(10.9)	12,981	(23.0)	8,159	(16.5)

(Notes) Comprehensive income: June 2013: 27,849million yen (- %) June 2012: (6,081)million yen (- %)

	Net income per share	Net income per share, fully diluted
	(Yen)	(Yen)
Three months ended June, 2013	47.17	-
Three months ended June, 2012	42.97	-

(Note) Percentage represent increase (decrease) from the corresponding period in the prior fiscal year.

(2) Consolidated financial position

	Total assets	Net assets	Equity ratio	Net assets per share
	(Millions of yen)	(Millions of yen)	%	(Yen)
As at June 30, 2013	795,234	461,579	58.0	2,429.13
As at March 31, 2013	771,032	437,909	56.7	2,304.42

(Note) Shareholders' equity : June 30, 2013: 461,234 million yen, March 31, 2013: 437,557 million yen.

2. Dividends

	Cash dividends per share				
	1st quarter	2nd quarter	3rd quarter	4th quarter	total
	(Yen)	(Yen)	(Yen)	(Yen)	(Yen)
Year ended March 31, 2013	-	22.00	-	22.00	44.00
Year ending March 31, 2014	-	-	-	-	-
Year ending March 31, 2014 (forecast)	-	29.00	-	29.00	58.00

(Note) Revise of dividends forecast : None

3. Consolidated Forecast for the Year Ending March 2014 (From April 1, 2013 to March 31, 2014)

	Net sales		Operating income		Ordinary income		Net income		Net income per share
	(Millions of yen)	%	(Millions of yen)	%	(Millions of yen)	%	(Millions of yen)	%	(Yen)
Half year ending September, 2013	222,000	15.7	30,000	6.4	28,500	17.7	19,000	30.8	100.06
Year ending March, 2014	460,000	14.3	70,000	31.5	67,500	31.4	42,000	(10.7)	221.20

1. Forecast for fiscal year ending March, 2014 which was announced on May 9, 2013 has not been revised.
(Assumed exchange rate for fiscal year ending March, 2014: USD1=JPY95, EUR1=JPY123)

2. Among the information that Terumo discloses, forecasts of financial performance on future projections contain potential risks and uncertainty since these are forecasts on projections made by Terumo based on limited information available at the moment of disclosure. Accordingly, it should be noted that actual results may differ from those forecasts on projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition.

4. Financial Statements

(1) Consolidated balance sheet

	As at March 31, 2013		As at June 30, 2013	
	Amount	%	Amount	%
(Assets)				
I Current assets	286,955	37.2%	292,409	36.8%
Cash and deposits	78,201		79,584	
Notes and accounts receivable-trade	95,008		96,060	
Merchandise and finished goods	54,346		57,703	
Work in process	9,265		9,396	
Raw material and supplies	21,568		22,886	
Deferred tax assets	11,258		9,351	
Other	18,528		18,737	
Allowance for doubtful accounts	(1,220)		(1,311)	
II Noncurrent assets	483,770	62.8%	502,357	63.2%
1. Property, plant and equipment	144,824	18.8%	149,211	18.8%
Buildings and structures	48,966		48,644	
Machinery, equipment and vehicles	46,366		45,805	
Land	21,827		21,910	
Lease assets	704		638	
Construction in progress	17,794		22,707	
Other	9,165		9,506	
2. Intangible assets	296,634	38.5%	307,206	38.6%
Goodwill	149,322		153,730	
Customer-related assets	90,706		93,763	
Other	56,604		59,712	
3. Investments and other assets	42,311	5.5%	45,938	5.8%
Investment securities	30,304		35,141	
Deferred tax assets	5,153		3,670	
Other	6,852		7,126	
III Deferred assets	306	0.0%	467	0.0%
Total assets	771,032	100.0%	795,234	100.0%

	As at March 31, 2013		As at March 31, 2013	
	Amount	%	Amount	%
(Liabilities)				
I Current liabilities	115,844	15.0%	112,643	14.2%
Notes and accounts payable-trade	37,515		36,701	
Short-term loans payable	18,046		18,018	
Current portion of long-term loans payable	3,762		3,943	
Lease obligations	277		255	
Income taxes payable	2,609		4,500	
Deferred tax liabilities	35		26	
Provision for bonuses	4,834		2,520	
Provision for directors' bonuses	109		27	
Notes and accounts payable-facilities	6,624		8,354	
Asset retirement obligations	420		72	
Other	41,611		38,222	
II Noncurrent liabilities	217,278	28.2%	221,011	27.8%
Bonds payable	80,000		80,000	
Long-term loans payable	78,712		80,092	
Lease obligations	439		395	
Deferred tax liabilities	49,659		51,457	
Provision for retirement benefits	1,247		1,330	
Provision for directors' retirement benefits	198		66	
Asset retirement obligations	155		156	
Other	6,865		7,511	
Total liabilities	333,122	43.2%	333,654	42.0%
I Shareholders' equity	419,999	54.5%	424,774	53.4%
Capital stock	38,716		38,716	
Capital surplus	52,103		52,103	
Retained earnings	329,188		333,967	
Treasury stock	(9)		(12)	
II Accumulated other comprehensive income	17,557	2.3%	36,460	4.6%
Valuation difference on available-for-sale securities	7,458		10,651	
Deferred gains or losses on hedges	-		(8)	
Foreign currency translation adjustment	10,099		25,817	
III Minority interests	352	0.0%	344	0.0%
Total net assets	437,909	56.8%	461,579	58.0%
Total liabilities, net assets	771,032	100.0%	795,234	100.0%

(2) Consolidated statement of income

	For the year ended			For the year ended		
	June 30, 2012			June 30, 2013		
	Amount		%	Amount		%
I Net sales		95,867	100.0%		111,090	100.0%
II Cost of sales		44,175	46.1%		54,099	48.7%
Gross profit		51,692	53.9%		56,990	51.3%
III Selling, general and administrative expenses		36,211	37.8%		43,661	39.3%
Operating income		15,481	16.1%		13,329	12.0%
IV Non-operating income						
Interest income	64			82		
Dividends income	56			56		
Royalty income	28			23		
Foreign exchange profit	-			577		
Equity in earnings of affiliates	33			81		
Other	331	514	0.5%	144	966	0.8%
V Non-operating expenses						
Interest expenses	263			368		
Sales discounts	154			166		
Foreign exchange losses	2,410			-		
Loss on disposal of inventories	0			43		
Other	185	3,013	3.1%	777	1,355	1.2%
Ordinary income		12,981	13.5%		12,940	11.6%
VI Extraordinary income						
Gain on sales of noncurrent assets	0			6		
Gain on transfer of business	-			262		
Subsidy income	875	875	0.9%	-	268	0.3%
VII Extraordinary expenses						
Loss on disposal of noncurrent assets	81			9		
Impairment loss	-			557		
Directors' retirement benefits	-	81	0.0%	33	600	0.5%
Income before income taxes		13,776	14.4%		12,608	11.4%
Income taxes-current	3,991			2,370		
Income taxes-deferred	1,609	5,600	5.9%	1,266	3,637	3.3%
Income before minority interests		8,175	8.5%		8,971	8.1%
Minority interests in income		16	0.0%		15	0.0%
Net income		8,159	8.5%		8,956	8.1%

(3) Consolidated statement of comprehensive income

(Millions of yen)

	For three months ended		For three months ended	
	June 30, 2012		June 30, 2013	
	Amount		Amount	
I Income before minority interests		8,175		8,971
II Other comprehensive income				
Valuation difference on available-for-sale securities	(1,016)		3,192	
Deferred gains or losses on hedges	(1)		(8)	
Foreign currency translation adjustments	(13,237)		15,694	
Share of other comprehensive income of associates accounted for using equity method	(1)	(14,256)	(0)	18,877
Comprehensive income		(6,081)		27,849
Attributable to:				
Shareholders of Terumo Corporation		(6,054)		27,857
Minority interests		(26)		(8)

5. Segment Information

[Reportable Segments]

(1) The First Quarter of Fiscal year ended March 31, 2013

(Millions of yen)

	For three months ended June 30, 2012					
	General Hospital Business	Cardiac & Vascular Business	Blood Management Business	Subtotal	Adjustment	Total
Sales:						
Sales to customer	38,182	41,056	16,628	95,867	-	95,867
Internal sales	-	-	-	-	-	-
Sales total	38,182	41,056	16,628	95,867	-	95,867
Segment income (loss)	5,959	6,859	287	13,106	2,374	15,481

Notes:

1. Segment income is adjusted to be consistent with operating income shown on the consolidated income statement.
2. Adjustment to segment income (loss), which amounted to 2,374 million yen, is the sum of 1,300 million yen for Inventories and 1,073 million yen for others.

(2) The First Quarter of Fiscal year ended March 31, 2014

(Millions of yen)

	For three months ended June 30, 2013					
	General Hospital Business	Cardiac & Vascular Business	Blood Management Business	Subtotal	Adjustment	Total
Sales and operating income:						
Sales to customer	39,445	50,125	21,520	111,090	-	111,090
Internal sales	-	-	-	-	-	-
Sales total	39,445	50,125	21,520	111,090	-	111,090
Segment income (loss)	4,788	8,696	577	14,062	(733)	13,329

Notes:

1. Segment income is adjusted to be consistent with operating income shown on the consolidated income statement.
2. Adjustment to segment income (loss), which amounted to (733) million yen, is the sum of (257) million yen for Inventories and (476) million yen for others.

(Note) Main products belonging to each business segment

Business segments	Main products
General Hospital business	
Disposable medical devices and medical electronics	Syringes, Needles, Blood collection tubes, Solution sets, I.V.catheters, Infusion pumps, Syringe pumps, etc.
Pharmaceuticals	I.V.solutions, Nutritious food, Prefilled syringes, CAPD systems, etc.
Diabetes care products	Blood glucose monitoring systems
Consumer Healthcare business	Digital Thermometers, Blood pressure monitors, Blood glucose monitors (OTC), etc.
Cardiac and Vascular business	
Interventional systems	Angiographic catheters, PTCA balloon catheters, Coronary stents, Neuro interventional coils, etc.
Cardiovascular systems	Oxygenators, Cardio-pulmonary bypass system, Left ventricular assist system, etc.
Vascular grafts	Artificial vascular grafts, Stent grafts
Blood Management business	
	Blood bags, Automated blood collection system, Therapeutic apheresis system, Cell expansion system, etc.